The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models.

3616Background: RET fusions/mutations drive oncogenesis in lung and thyroid cancers, and several other malignancies. Selective RET inhibitors (selpercatinib/pralsetinib) are active in patients with...